|
Referencias
1- Messerli FH, Williams B, Ritz E. Essential
hypertension. The Lancet.
August
18, 2.007; 370(9587):591-603.
2-
Doval HC, Tajer CD. Evidencias en Cardiología IV. De los
ensayos clínicos a las conductas terapeúticas.
Ed. CEDIC, 2.005.
3- The ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group. Major cardiovascular
events in hypertensive patients randomized to doxazosin
vs chlorthalidone: the antihypertensive and
lipid-lowering treatment to prevent heart attack trial (ALLHAT).
JAMA. 2000 Apr 19;283(15):1967-75.
4- The ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group. The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Major outcomes in high-risk hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or
calcium channel blocker vs diuretic: The
Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT). JAMA. 2002 Dec
18;288(23):2981-97.
5- Stevo Julius. The ALLHAT study: if you believe in
evidence-based medicine, stick to it! Journal of
Hypertension. 2003, 21:453–454
6- Appel LJ. The verdict from ALLHAT--thiazide diuretics
are the preferred initial therapy for hypertension.
JAMA. 2.002, December 18;288(23):3039-42.
7- Peter C. Austin, Muhammad M. Mamdani, Karen Tu,
Merrick Zwarenstein.
Changes in Prescribing Patterns Following Publication of
the ALLHAT Trial. JAMA, January 7, 2004—Vol 291, No. 1.
8- The Seventh Report of the Join National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure. The JNC 7 Report. JAMA. 2.003; 289:
2560-2572.
9- Jay I. Meltzer. A clinical specialist in hypertension
critiques JNC 7. American journal of hypertension. 2005
July; 18(7):894-898
10- Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA,
Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ,
Marley JE, Morgan TO, West MJ, for the Second Australian
National Blood Pressure Study Group. A comparison of
outcomes with angiotensin-converting--enzyme inhibitors
and diuretics for hypertension in the elderly. The New
England Journal of Medicine. 2003 February 13;
348(7):583-92.
11- Elliott WJ, Meyer PM. Incident diabetes in clinical
trials of antihypertensive drugs: a network
meta-analysis. The Lancet. 2007 Jan 20;369(9557):201-7.
12- Scheen AJ. Renin-angiotensin system inhibition
prevents type 2 diabetes mellitus. Part 1. A
meta-analysis of randomised clinical trials. Diabetes
Metab 2004,30,487-496.
13- Psaty BM, Lumley T, Furberg CD, Schellenbaum G,
Pahor M, Alderman MH, Weiss NS. Health outcomes
associated with various antihypertensive therapies used
as first-line agents: a network meta-analysis. JAMA. May
21 2003; 289(19):2534-44.
14- Andraws R, Brown DL Effect of inhibition of the
renin-angiotensin system on development of type 2
diabetes mellitus (meta-analysis of randomized trials).
The American journal of cardiology. 2007 Apr
1;99(7):1006-12. Epub 2007 Feb 16.
15- Mancia G, Grassi G, Zanchetti A. New-onset diabetes
and antihypertensive drugs. Journal of Hypertension.
2006, January 24:3–10.
16- Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr.
Angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers for prevention of type 2 diabetes: a
meta-analysis of randomized clinical trials. Journal of
the American College of Cardiology. September 6, 2.005
17- Bangalore S, Parkar S, Grossman E, Messerli FH. A
meta-analysis of 94,492 patients with hypertension
treated with beta blockers to determine the risk of
new-onset diabetes mellitus. The American journal of
cardiology. October 15, 2.007
18- Burke TA, Sturkenboom MC, Ohman-Strickland PA,
Wentworth CE, Rhoads GG. The effect of antihypertensive
drugs and drug combinations on the incidence of
new-onset type-2 diabetes mellitus. Pharmacoepidemiology
and Drug Safety. 2007 Sep;16(9):979-87.
19- Beevers DG. The end of beta blockers for
uncomplicated hypertension? The Lancet. 2005 Oct 29-Nov
4;366(9496):1510-2.
20- Simon KH Lam, Andrew Owen. Correspondence. Incident
diabetes in clinical trials of antihypertensive drugs.
The Lancet 2007; 369: 1513-1514.
21- GD Johnston. Correspondence. Incident diabetes in
clinical trials of antihypertensive drugs. The Lancet
2007; 369:1514.
22- Cooper ME, Tikellis C, Thomas MC. Preventing
diabetes in patients with hypertension: one more reason
to block the renin-angiotensin system. Journal of
hypertension. Supplement : official journal of the
International Society of Hypertension. 2006
Mar;24(1):S57-63.
23- Scheen AJ. Renin-angiotensin system inhibition
prevents type 2 diabetes mellitus. Part 2. Overview of
physiological and biochemical mechanisms. Diabetes
Metab 2004,30,498-505.
24- Carter BL, Basile J. Development of diabetes with
thiazide diuretics: the potassium issue. Journal of
clinical hypertension (Greenwich, Conn.). November 2005;
7(11):638-40.
25- G. Mancia The association of hypertension and
diabetes: prevalence, cardiovascular risk and protection
by blood pressure reduction. Acta Diabetol (2005)
42:S17–S25.
26- Franz H. Messerlia, Ehud Grossmanb and Gastone
Leonettic. Antihypertensive therapy and new onset
diabetes. Journal of Hypertension 2004, 22:1845–1847
27- Nilsson PM, Cifkova R, Kjeldsen SE, Mancia G. Update
on hypertension management: Prevention of type 2
diabetes mellitus with antihypertensive drugs. European
Society of Hypertension Scientific Newsletter. 2006
December 24(12): 2478-82.
28- Verdecchia P, Reboldi G, Angeli F, Borgioni C,
Gattobigio R, Filippucci L, Norgiolini S, Bracco C,
Porcellati C. Adverse prognostic significance of new
diabetes in treated hypertensive subjects. Hipertensión.
May, 2.004
29- Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A,
Rosengren A, Andersson OK. Diabetes in treated
hypertension is common and carries a high cardiovascular
risk: results from a 28-year follow-up. Journal of
hypertension. June 2.007; 25(6):1311-7.
30- Dunder K, Lind L, Zethelius B, Berglund L, Lithell
H. Increase in blood glucose concentration during
antihypertensive treatment as a predictor of myocardial
infarction: population based cohort study. British
Medical Journal. 2003 Mar 29;326(7391):681
31- Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell
CJ, Kannel WB, Levy D. Impact of high-normal blood
pressure on the risk of cardiovascular disease. The New
England Journal of Medicine. 2001 Nov 1;345(18):1291-7.
32- Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM,
Pressel SL, Davis BR; SHEP Collaborative Research Group.
Long-term effect of diuretic-based therapy on fatal
outcomes in subjects with isolated systolic hypertension
with and without diabetes. The American journal of
cardiology. 2005 January 1;95(1):29-35.
33- Alberto Zanchetti. Evidence-based medicine in
hypertension: what type of evidence? Journal of
Hypertension 2005, 23:1113–1120.
34- Williams B. Evolution of hypertensive disease: a
revolution in guidelines. The Lancet. July 1 2006;
368(9529):6-8
35- Remuzzi G, Ruggenenti P. Overview of randomised
trials of ACE inhibitors. The Lancet. 2006 Aug
12;368(9535):555-6.
36- Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG,
Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT,
Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S;
ASCOT Investigators. Role of blood pressure and other
variables in the differential cardiovascular event rates
noted in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). The
Lancet. 2005, September 10-16;366(9489):907-13.
37- Jan A Staessen, Willem H Birkenhäger. Evidence that
new antihypertensives are superior to older drugs. The
Lancet. September 2.005.; 10-16;366(9489):869-71.
38- McMurray JJV. ACE Inhibitors in Cardiovascular
Disease — Unbeatable? Editorial. N Engl J Med
358;15:1615-1616.
39- The ONTARGET Investigators. Telmisartan, ramipril,
or both in patients at high risk for vascular events. N
Engl J Med 2008;358:1547-59.
|
